Format

Send to

Choose Destination
Vaccine. 2014 Apr 25;32(20):2337-44. doi: 10.1016/j.vaccine.2014.02.066. Epub 2014 Mar 12.

Development of a Rift Valley fever virus viremia challenge model in sheep and goats.

Author information

1
National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, Manitoba, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address: hana.weingartl@inspection.gc.ca.
2
University of Wyoming, Laramie, WY, USA.
3
National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, Manitoba, Canada.
4
Arthropod-Borne Animal Diseases Research Unit, ARS, USDA, Manhattan, KS, USA.

Abstract

Rift Valley fever virus (RVFV), a member of the family Bunyaviridae, causes severe to fatal disease in newborn ruminants, as well as abortions in pregnant animals; both preventable by vaccination. Availability of a challenge model is a pre-requisite for vaccine efficacy trials. Several modes of inoculation with RVFV ZH501 were tested on goats and sheep. Differences in development of infectious viremia were observed between animals inoculated with RVFV produced in mosquito C6/36 cells compared to Vero E6 cell-produced inoculum. Only C6/36-RVFV inoculation led to development of viremia in all inoculated sheep and goats. The C6/36 cell-produced RVFV appeared to be more infectious with earlier onset of viremia, especially in sheep, and may also more closely represent a field situation. Goats were somewhat more resistant to the disease development with lower and shorter infectious virus viremia, and with only some animals developing transient increase in rectal temperature in contrast to sheep. In conclusion, a challenge protocol suitable for goat and sheep vaccine efficacy studies was developed using subcutaneous inoculation of 10(7)PFU per animal with RVFV ZH501 produced in C6/36 cells.

KEYWORDS:

Real-time RT-PCR; Rift Valley fever; Viremia; Virus isolation

PMID:
24631070
DOI:
10.1016/j.vaccine.2014.02.066
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center